RecruitingRecruiting
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
NCT07313462 · University Hospital, Strasbourg, France
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
Eligibility criteria
Inclusion Criteria:
* Patients with RRMS onset after age 50
* Patients who started their first disease-modifying therapy within 2 years of the first symptoms
* Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
* Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
Exclusion Criteria:
\- Patients with early progressive MS
Study design
Enrollment target: 830 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-02-07
Estimated completion: 2026-02
Last updated: 2026-01-02
Primary outcomes
- • Time to First Clinical Inflammatory Relapse (Up to 12 months)
Sponsor
University Hospital, Strasbourg, France · other
Contacts & investigators
ContactNicolas Collongues, MD · contact · nicolas.collongues@chru-strasbourg.fr · 33 3.88.12.87.33
All locations (1)
Centre d'Investigation Clinique - CHU de Strasbourg - FranceRecruiting
Strasbourg, France